Credit Available: 1.00 AMA PRA Category 1 credit(s)

Course Director: Naim Alkhouri, MD, FAASLD

Course Faculty: Prof. Dr. med. Frank Tacke MD, PhD, MHBA and Prof. Dr. Jörn M. Schattenberg

Presented at UEG 2025, this activity explores the growing body of clinical data surrounding guideline-recommended treatment for metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). Listen to an international panel of experts discuss real-world cases to optimize pharmacologic management of MASLD/MASH. Find out the best way to screen patients and diagnose MASLD/MASH using current noninvasive testing methods in this new treatment era.

Credit Available: 1.00 AMA PRA Category 1 credit(s)

Course Director: Michael Roden, MD

Course Faculty: Amalia Gastaldelli, PhD and Michael Trauner, MD

Presented at EASD 2025, this activity explores the real-world application of liver-directed therapies for metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). Join leading European experts as they share insights on the use of thyroid hormone receptor-β (THR-β) agonists through engaging case-based discussions. Stay up to date on the latest evidence in noninvasive testing and other therapeutic options in advanced clinical development. 

Credit Available: .75 AMA PRA Category 1 credit(s)

Course Director: Meena B. Bansal, MD, FAASLD

Course Faculty: Professor Laurent Castera, MD, PhD and Prof. Dr. med. Frank Tacke, MD, PhD, MHBA

Presented at Paris MASH 2025, this activity examines the practical aspects of integrating liver-directed therapy for the treatment of metabolic-associated steatotic liver disease and its related metabolic-associated steatohepatitis. Tune in to hear an international panel of experts discuss current successes and challenges with real-world use of thyroid hormone receptor-β agonists through several case-based scenarios. Hear the latest data around noninvasive testing and other treatments in late-stage development.

Credit Available: 1.00 AMA PRA Category 1 credit(s)

Course Director: Naim Alkhouri, MD, FAASLD

Course Faculty: Prof. Dr. med. Frank Tacke, MD, PhD, MHBA and Professor Laurent Castera, MD, PhD

Presented at the International Liver Congress (or EASL 2025), this activity explores the growing body of data surrounding new and emerging treatments for metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis. Hear leading hepatology experts discuss the most advanced noninvasive methods for diagnosing liver fibrosis. Several case-based scenarios are presented with discussions around optimizing pharmacologic management liver disease approaches a new treatment era.

Credit Available: 1.00 AMA PRA Category 1 credit(s)

Course Director: Naim Alkhouri, MD, FAASLD

Course Faculty: Meena B. Bansal, MD, FAASLD and Winston Dunn, MD

Presented at Digestive Disease Week (or DDW 2025), this activity examines current evidence around the clinical efficacy and safety data of approved and emerging disease-specific therapies for the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). Hepatology experts lead case-based discussions for navigating algorithms for noninvasive testing and optimizing pharmacologic management with the evolving armamentarium of treatments for MASLD/MASH.

Credit Available: 1.00 AMA PRA Category 1 credit(s)

Course Director: Meena B. Bansal, MD

Course Faculty: Laurent Castera, MD, PhD and Mary E. Rinella, MD

Presented at The EASL SLD Summit 2025, a new era of disease management is here with FDA approval of the first metabolic-associated steatohepatitis (MASH)-specific therapy and its review by the European Medical Agency, along with several other agents in advanced stages of development. This activity will explore the mechanism of action of thyroid hormone receptor-β (THR-β) agonists and the efficacy of these agents in the treatment of MASH. Case-based scenarios will explore the best way to noninvasively assess disease staging and manage patients using the most recently available clinical and safety data.

Credit Available: 1.00 AMA PRA Category 1 credit(s)

Course Director: Naim Alkhouri, MD, FAASLD

Course Faculty: Elisabetta Bugianesi, MD, PhD, and Michael Trauner, MD.

Presented at the United European Gastroenterology 2024 meeting, this activity presents emerging considerations around optimizing the management of patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). The recent approval in the United States of the first disease-specific therapy has created the potential for improved patient-centered care. Leading gastroenterology and hepatology experts discuss the best methods for screening, diagnosis, and treatment in this new era of disease-specific care.

Credit Available: 1.00 AMA PRA Category 1 credit(s)

Course Director: Meena B. Bansal, MD, FAASLD

Course Faculty: Juan M. Pericàs, MD, MPH, PhD, and Michael Roden, MD

Presented at the European Association for the Study of Diabetes 2024 meeting, this activity explores considerations around screening for metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) in patients with type 2 diabetes. Current clinical trial data of MASH-specific therapies will be examined along with the mechanism of action of thyroid hormone receptor- b (THR-b) agonists. With the recent approval in the United States of the first MASH-specific therapy ushers in a new era for patient-centered care, several case-based scenarios will examine the most current approaches to screening, diagnosis, and treatment.

Credit Available: 1.00 AMA PRA Category 1 credit(s)

Course Director: Meena B. Bansal, MD, FAASLD

Course Faculty: Quentin M. Anstee, MBBS, PhD, FRCP, and Laurent Castera, MD, PhD.

Presented at the Paris MASH 2024 meeting, this activity examines emerging treatments that reduce fibrosis in patients with metabolic dysfunction-associated steatohepatitis (MASH). The recent approval in the United States of the first disease-specific therapy has created the potential for improved patient-centered care. Find out how hepatology thought leaders from across the globe are utilizing noninvasive testing to identify and risk stratify patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and MASH. Case-based discussions reveal how to individualize treatment and optimize outcomes in this new era of patient care.

Credit Available: 1.00 AMA PRA Category 1 credit(s)

Course Director: Meena B. Bansal, MD, FAASLD

Course Faculty: Quentin M. Anstee, MBBS, PhD, FRCP, and Elisabetta Bugianesi, MD, PhD.

Presented at the International Liver Congress, EASL 2024, this activity will explore new innovations in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). The recent approval of the first disease-specific therapy ushers in a new era for patient-centered care. Hear leading hepatologists from around the world consider the recent advancements in treatment through case-based discussions. Also, find out the best ways to identify patients who will benefit most in this new area of disease-specific care.

Credit Available: 1.25 AMA PRA Category 1 credit(s)

Course Director: Meena B. Bansal, MD, FAASLD

Course Faculty: Naim Alkhouri, MD, FAASLD and Mazen Noureddin, MD, MHSc

Presented at Digestive Disease Week, DDW 2024, this activity explores the latest clinical efficacy and safety data of approved and emerging disease-specific therapies for the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). Hepatology experts will discuss the mechanism of action of the first US Food and Drug Administration-approved thyroid hormone receptor-β (THR-β) agonist and examine case-based scenarios for optimizing pharmacologic management MASLD/MASH in this new treatment era. Considerations around disease staging will also be presented to ensure optimal patient management.